Sign in →

Test ID ERPR Estrogen/Progesterone Receptor, Semi-Quantitative Immunohistochemistry, Manual

Reporting Name

ER/PR Semi Quant IHC Manual

Useful For

Guiding decisions on hormonal therapy in patients with breast carcinomas

 

This test is not useful for cases of lobular carcinoma in situ.

Clinical Information

The steroid hormone receptors, estrogen receptor (ER) and progesterone receptor (PR), are commonly used in the management of women with breast cancer. ER and PR status provide an indication of prognosis and of the potential benefit from hormonal therapy. Generally, ER/PR-positive tumors are more likely to respond to endocrine therapy and have a better prognosis, stage-for-stage, than receptor-negative tumors.

 

While the test can be performed on any formalin-fixed, paraffin-embedded tissue, it is infrequently used for non-breast cancer specimens.

Interpretation

Immunoperoxidase-stained slides are examined microscopically by the consulting anatomic pathologist and interpreted as negative (<1% reactive cells), or positive. The percent of reactive cells is provided in the report.

Report Available

4 to 6 days

Day(s) Performed

Monday through Friday

Clinical Reference

1. Hammond ME, Hayes DF, Dowsett M, et al: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. Arch Pathol Lab Med. 2010 Jun;134(6):907-22. doi: 10.1043/1543-2165-134.6.907. Erratum in: Arch Pathol Lab Med. 2010 Aug;134(8):1101

2. Allison KH, Hammond MEH, Dowsett M, et al: Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309

Method Name

Semi-Quantitative Immunohistochemistry

Specimen Type

Special


Ordering Guidance


This test is for prognostic purposes only.

 

For diagnostic purposes, order PATHC / Pathology Consultation and then request the stains.

 

Estrogen/progesterone receptor testing is not appropriate and not performed for cases of lobular carcinoma in situ.



Shipping Instructions


Attach the green pathology address label included in the kit to the outside of the transport container.



Necessary Information


1. Include accompanying pathology report stating the final diagnosis. If not available, a preliminary diagnosis is acceptable.

2. Information regarding fixative used, time to fixation, and duration of fixation is required. The following questions, as stated on the order form or presented electronically, must be answered:

a. "Was specimen fixed in 10% neutral buffered formalin within 1 hour from surgical collection time? Yes, No, or Unknown."

b. "Has specimen been fixed in 10% neutral buffered formalin for 6 to 72 hours? Yes, No, or Unknown."

c. "Was tissue decalcified? Yes, No, or Unknown."

d. "Tumor type? Primary breast carcinoma, metastatic breast carcinoma, or non-breast tumor."

e. "Tumor classification? Invasive breast carcinoma, ductal carcinoma in situ, metastatic breast carcinoma, micro-invasive breast carcinoma, solid/intracystic papillary carcinoma, or non-breast tumor."



Specimen Required


Supplies: Pathology Packaging Kit (T554)

Specimen Type: Breast carcinoma

Preferred: A paraffin-embedded tissue block containing in-situ, invasive or metastatic breast carcinoma tissue that has been fixed in 10% neutral buffered formalin within 1 hour from surgical collection time and for a total of 6 to 72 hours and shipped at ambient temperature

Acceptable: 3 unstained sections, containing carcinoma, on charged slides cut at 4 microns <1 month ago and shipped at ambient temperature

Collection Instructions: Submit paraffin-embedded carcinoma tissue

 

Specimen Type: Non-breast carcinoma

Preferred: A paraffin-embedded tissue block containing carcinoma tissue that has been fixed in 10% neutral buffered formalin and shipped at ambient temperature

Acceptable: 3 unstained sections, containing carcinoma, on charged slides cut at 4 microns <1 month ago and shipped at ambient temperature

Collection Instructions: Submit paraffin-embedded carcinoma tissue

 

Additional Information:

1. According to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines, estrogen/progesterone receptor protein immunohistochemical test results are only valid for nondecalcified, paraffin-embedded specimens fixed in 10% neutral buffered formalin within 1 hour from surgical collection time and for a total time of 6 to 72 hours. Delay to fixation, under- or overfixation may affect these results.

2. Paraffin blocks will be returned with final report.


Forms

If not ordering electronically, complete, print, and send 1 of the following forms with the specimen:

-Oncology Test Request (T729)

-Immunohistochemical (IHC)/In Situ Hybridization (ISH) Stains Request (T763)

Specimen Stability Information

Specimen Type Temperature Time Special Container
Special Ambient (preferred)
  Refrigerated 

Reference Values

Negative: <1% reactive cells

Positive: ≥1% reactive cells

Test Classification

This test has been modified from the manufacturer's instructions. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the US Food and Drug Administration.

CPT Code Information

88360 x 2

LOINC Code Information

Test ID Test Order Name Order LOINC Value
ERPR ER/PR Semi Quant IHC Manual 10480-2

 

Result ID Test Result Name Result LOINC Value
70965 Interpretation 50595-8
70966 Participated in the Interpretation No LOINC Needed
70967 Report electronically signed by 19139-5
70969 Material Received 81178-6
MA002 Fixed in 10% NB formalin w/in 1 hr 8100-0
MA003 Fixed in 10% NB formalin 6-72 hrs 8100-0
MA004 Tumor type 44638-5
MA005 Tumor classification 21918-8
MA044 Tissue was decalcified 8100-0
71620 Disclaimer 62364-5
71834 Case Number 80398-1

Disease States

  • Breast cancer
Mayo Clinic Laboratories | IHC Catalog Additional Information:

mcl-ihc-interp